Q4 2012 · 10-K
Revenue$26.98M$26.98M −16.1% vs Q4 2011−72.0% vs Q3 2012
Net income—
EPS Diluted-$0.41-$0.41 N/M vs Q4 2011N/M vs Q3 2012
Operating Incomederived-$43,900,000N/M
Operating Cash Flowderived-$22,459,000N/M
Free Cash Flowderived-$25,843,000N/M
Margins · derived
Operating margin-162.7%−140.8 pt vs Q4 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2012 | Q4 2011 | Q4 2010 |
|---|---|---|---|
| Revenue | $26.98M | $32.15M | $16.77M |
| Net Income | — | -$6.97M | -$11.65M |
| EPS Diluted | -$0.41 | -$0.07 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR